Elevated Lp(a) levels are not yet driving more aggressive lipid lowering therapy, according to an analysis of Lp(a) testing in patients in a university-based health system since 2013.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.